Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside ...

Recent performance context for Ipsen Ipsen (ENXTPA:IPN) has drawn investor attention after a period of strong share price performance, with the stock showing positive returns over the past week, month ...

Global biopharmaceutical group Ipsen is using AI to help leaders sharpen how they give feedback – transforming a learnable ...

Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026 of Ipsen S.A. Formalities for making ...

After a lengthy strategic review, Ipsen’s plan to hive off its consumer health care (CHC) business is gaining traction. With the blessing of its board of directors, Ipsen entered exclusive talks with ...

New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused ...

FY 2025 sales growth of 10.9% at CER 1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1% 1), Rare Disease (102.5% 1) and Neuroscience (9.7% 1); Somatuline® sales ...

Ipsen to request re-examination of CHMP opinion on palovarotene as a potential treatment for fibrodysplasia ossificans progressiva in E.U. FOP is an ultra-rare disease that continuously and ...

On the heels of reaching an acquisition agreement that brings Ipsen a commercialized follicular lymphoma drug, the Paris-based drugmaker is expanding its reach in cancer through a licensing deal that ...

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announced today the closing of the acquisition of Syntaxin, a UK-based private life sciences company specialized in botulinum toxin engineering. Under the ...

According to deal terms announced Monday, Paris-based Ipsen will pay Exicure $20 million up front to begin the alliance. In exchange, Ipsen gains exclusive options to license the Huntington’s disease ...

New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda (tovorafenib) represents ...